WynnVision LLC, founded in 2016 by Dr. Kenneth J. Wynne, is a pioneering brand specializing in the development of rapid treatments for preventing infections in commercially available medical devices.

With a team of scientist-engineers, WynnVision is committed to engineering the surface of these devices to introduce bacteria-killing properties on contact and minimize biofilm formation. This cutting-edge technology addresses the pressing needs of the healthcare community in combating healthcare associated infections (HAIs), which contribute to elevated mortality rates and reduced quality of life for patients. Identifying Catheter Associated Urinary Tract Infections (CAUTIs) and Ventilator Associated Pneumonia (VAP) as frequent HAIs, WynnVision aims to provide practical solutions with its proprietary treatment technology.

Backed by decades of research experience and scientific advancements, WynnVision's broad-spectrum approach effectively targets a range of pathogens. The ultimate mission of WynnVision is to save lives, alleviate economic burdens on patients and healthcare providers, and enhance the overall quality of patient care. By leveraging expertise in surface characterization, antimicrobial efficacy, biocompatibility, and conducting supplementary tests, WynnVision ensures the highest standards of quality and safety in its products and services.

With a dedicated team led by Dr. Kenneth J. Wynne, WynnVision is at the forefront of innovation, providing real solutions to critical healthcare challenges.

Located at 800 E Leigh St, Richmond, VA, WynnVision LLC embodies a commitment to excellence and is poised to make a lasting impact in the fight against HAIs